Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iguratimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF known ✓ | P14174 | 1/20 | 1.00 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iguratimod SCHEMBL29366981 | 1.00 | PTGS1 (1.00) | PTGS1ADORA3MIFPDE4APDE4D | |
| Iguratimod SCHEMBL5455197 | 0.99 | PTGS1 (0.98) | PTGS1ADORA3MIFPDE4APDE4D | |
| Iguratimod SCHEMBL29230458 | 0.93 | PTGS1 (0.87) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL10417305 | 0.92 | PTGS1 (0.85) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL7863101 | 0.90 | PTGS1 (0.81) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL10415850 | 0.89 | PTGS1 (0.80) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL10415468 | 0.88 | ADORA3 (0.78) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL10415410 | 0.87 | PTGS1 (0.77) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL31114276 | 0.87 | PTGS1 (0.77) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL30753982 | 0.87 | PTGS1 (0.77) | PTGS1ADORA3MIFPDE4APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1664 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367267-A1 | TREATING AUTOIMMUNE DISEASES WITH INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO AN AGENT | LIRUM THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250336533-A1 | Methods and Systems for Evaluation of Lupus Based on Ancestry-Associated Molecular Pathways | AMPEL BIOSOLUTIONS LLC (US) | 2025-10-30 | — | — | US | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4616404-A1 | METHODS AND SYSTEMS FOR EVALUATION OF LUPUS BASED ON ANCESTRY-ASSOCIATED MOLECULAR PATHWAYS | Ampel Biosolutions, LLC (US) | 2025-09-17 | — | — | EP | claimed |
| CN-120131576-A | Iguratimod tablet and preparation method thereof | 天津力生制药股份有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-120025434-A | Radioactive probe68Ga-NOTA-mAbKv 1.3Synthetic method and application of (2) | 华中科技大学同济医学院附属协和医院 | 2025-05-23 | — | — | CN | claimed |
| CN-119776277-B | Treg cell expansion culture process | 上海赛尔欣生物医疗科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| EP-4547265-A1 | TREATING AUTOIMMUNE DISEASES WITH INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO AN AGENT | Lirum Therapeutics, Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| CN-222833080-U | Quantitative filling device for Iguratimod powder | 河南诺美药业有限公司 | 2025-05-06 | — | — | CN | claimed |
| EP-1140179-A2 | USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| EP-0695547-B1 | IMMUNOMODULATOR, CELL ADHESION INHIBITOR, AND AGENT FOR TREATING AND PREVENTING AUTOIMMUNE DISEASES | TOYAMA CHEMICAL CO LTD (JP) | 2001-08-08 | — | — | EP | claimed |
| US-6166068-A | Immunomodulator, cell adhesion inhibitor, and agent for treating, and preventing autoimmune diseases | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | claimed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | claimed |
| US-5922755-A | ADMINSTERING 4H-1-BENZOPYRAN-4-ONE DERIVATIVE | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | claimed |
| EP-0927555-A1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia | Sankyo Company Limited (JP) | 1999-07-07 | — | — | EP | claimed |
| EP-0695547-A1 | IMMUNOMODULATOR, CELL ADHESION INHIBITOR, AND AGENT FOR TREATING AND PREVENTING AUTOIMMUNE DISEASES | TOYAMA CHEMICAL CO., LTD. (JP) | 1996-02-07 | — | — | EP | claimed |
| US-4954518-A | Antiinflammatory agents | TOYAMA CHEMICAL COMPANY, LTD. (JP) | 1990-09-04 | — | — | US | claimed |